Ihor Buryak

Recent publications · Crossref

5 total works indexed

1. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

   · 2008 · cited 3,146x

2. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

   · 2019 · cited 2,931x

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

   · 2019 · cited 2,788x

4. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

   · 2019 · cited 1,873x

5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

   · 2020 · cited 1,523x

via Crossref · CC0

Wikidata facts